NCT06740318 (A-HEP) is a NA clinical trial of Motivational enhancement therapy in Alcoholic Hepatitis (AH), sponsored by Nina Kimer.

Who is sponsoring NCT06740318?

NCT06740318 is sponsored by Nina Kimer.

What drugs are being tested in NCT06740318?

Interventions in NCT06740318: Motivational enhancement therapy.

What condition does NCT06740318 study?

NCT06740318 studies Alcoholic Hepatitis (AH).

Is NCT06740318 still recruiting?

NCT06740318 is currently recruiting now. Last updated 27 February 2025.

Last reviewed 2025-02-27 · How we verify

NCT06740318: A-HEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recompensation in Alcohol Related Hepatitis

Recruiting now NA Last updated 27 February 2025

What this trial tests

NA trial testing Motivational enhancement therapy in Alcoholic Hepatitis (AH) in 160 participants. Currently enrolling.

Timeline

25 November 2024

Primary endpoint
31 December 2028

31 December 2029

Quick facts

Lead sponsor	Nina Kimer
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	25 November 2024
Primary completion	31 December 2028
Estimated completion	31 December 2029
Sites	1 location across Denmark

Drugs / interventions tested

Motivational enhancement therapy

Conditions studied

Alcoholic Hepatitis (AH) — all drugs for Alcoholic Hepatitis (AH) →

Sponsor

Nina Kimer — full company profile →

Who can join

18 and older, any sex, with Alcoholic Hepatitis (AH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism. The aim of this study is to assess the impact of alcohol cessation in patients with alcohol related hepatitis and gain knowledge of the metabolic and genetic functions of the liver during remission and recompensation from alcohol related hepatitis. The study will assess 1. The effect of alcohol cessation on the liver. 2. The biological mechanisms involved in healing after alvohol-cessation 3. The effect of motivational enhcament therapy in alcohol cessation after alcohol related hepatitis. 4. The metabolic changes of lipids and proteins in the liver Participants are offered motivational enhancement therapy and standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Motivational enhancement therapy

Trials testing the same drug.

NCT05796791 — Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder · EARLY_PHASE1 · completed
NCT02883361 — Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors · Phase 2, PHASE3 · withdrawn

Other Nina Kimer trials

Trials by the same sponsor.

NCT03027635 — PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06740318 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nina Kimer
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing